MGA Releases Economic Impact Report for Multinational Pharmaceutical Company
In a newly released report, MGA highlights the broad economic impact of Otsuka in the United States.
New MGA Analysis Finds Drug Rebates Not Associated with List Price Increases
In a new report, MGA examines the role of rebates among a subset of prescription drugs with the biggest price hikes between 2018 and 2023.
New MGA White Paper Examines Consequences of Regulatory Uncertainty for Employee Ownership
In a new white paper, Alex Brill details the consequences of regulatory uncertainty for businesses and provides a close look at the ongoing uncertainty facing companies owned by ESOPs.
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
- How Pharmaceutical Tariffs Will Affect US Health Care Costs
- MGA Releases New Report Quantifying the Economic Impact of Healthcare Distributors
- The Unsung Hero of the OBBBA: Permanent Expensing
- Alex Brill Interviewed by Biosimilars Review & Report
- MGA Releases New White Paper on Medicare Price Negotiations and Drug Competition
- The 340B Program’s Negative Impact on Pharmaceutical Innovation
